Literature DB >> 1315326

Highly sensitive enhanced chemiluminescence immunodetection method for herpes simplex virus type 2 Western immunoblot.

J Dalessio1, R Ashley.   

Abstract

Three Western blot (immunoblot) methods for detecting antibodies to herpes simplex virus type 2 were compared: (i) nitrocellulose blots with 4-chloro-1-naphthol immunostaining (4CN-WB); (ii) polyvinylidene difluoride (PVDF) blots with 3,3',5,5'-tetramethylbenzidene immunostaining (TMB-WB); and (iii) PVDF blots with enhanced chemiluminescence (ECL-WB). TMB-WB was 10-fold more sensitive than 4CN-WB, while ECL-WB was as much as 500-fold more sensitive.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1315326      PMCID： PMC265202          DOI： 10.1128/jcm.30.4.1005-1007.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection.

Authors:  J Kahlon; F D Lakeman; M Ackermann; R J Whitley
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

2.  Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Presence of type 2 antibody in acute serum samples.

Authors:  D I Bernstein; M A Lovett; Y J Bryson
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

3.  Antibody response to type-common and type-unique epitopes of herpes simplex virus polypeptides.

Authors:  D I Bernstein; Y J Bryson; M A Lovett
Journal:  J Med Virol       Date:  1985-03       Impact factor: 2.327

4.  The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes.

Authors:  L A Koutsky; R L Ashley; K K Holmes; C E Stevens; C W Critchlow; N Kiviat; C M Lipinski; P Wølner-Hanssen; L Corey
Journal:  Sex Transm Dis       Date:  1990 Apr-Jun       Impact factor: 2.830

5.  Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.

Authors:  G J Mertz; R Ashley; R L Burke; J Benedetti; C Critchlow; C C Jones; L Corey
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

6.  Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor.

Authors:  Z A Brown; J Benedetti; R Ashley; S Burchett; S Selke; S Berry; L A Vontver; L Corey
Journal:  N Engl J Med       Date:  1991-05-02       Impact factor: 91.245

7.  Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus.

Authors:  R L Ashley; L Corey
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

8.  The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections.

Authors:  D I Bernstein; M A Lovett; Y J Bryson
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

9.  Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2.

Authors:  R Ashley; A Cent; V Maggs; A Nahmias; L Corey
Journal:  Ann Intern Med       Date:  1991-10-01       Impact factor: 25.391

10.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.

Authors:  R L Ashley; J Militoni; F Lee; A Nahmias; L Corey
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948
View more
  10 in total

Review 1.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

2.  FlaA, a putative flagellar outer sheath protein, is not an immunodominant antigen associated with Lyme disease.

Authors:  Y Ge; N W Charon
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

Review 3.  Laboratory techniques in the diagnosis of herpes simplex infection.

Authors:  R L Ashley
Journal:  Genitourin Med       Date:  1993-06

4.  Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.

Authors:  A Wald; L Corey; R Cone; A Hobson; G Davis; J Zeh
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Authors:  Rehan Akbani; Karl-Friedrich Becker; Neil Carragher; Ted Goldstein; Leanne de Koning; Ulrike Korf; Lance Liotta; Gordon B Mills; Satoshi S Nishizuka; Michael Pawlak; Emanuel F Petricoin; Harvey B Pollard; Bryan Serrels; Jingchun Zhu
Journal:  Mol Cell Proteomics       Date:  2014-04-28       Impact factor: 5.911

6.  Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection.

Authors:  R Ashley; A Wald; L Corey
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Authors:  Francois-Xavier Mbopi-Kéou; Laurent Bélec; Julie Dalessio; Jérôme Legoff; Gérard Grésenguet; Philippe Mayaud; David W G Brown; Rhoda Ashley Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells.

Authors:  E Manickan; M Francotte; N Kuklin; M Dewerchin; C Molitor; D Gheysen; M Slaoui; B T Rouse
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV.

Authors:  M B McChesney; J R Collins; D Lu; X Lu; J Torten; R L Ashley; M W Cloyd; C J Miller
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Cervical antibodies to herpes simplex virus proteins in pregnancy and puerperium: a pilot study.

Authors:  D H Watts; J M Guise; Z Brown; L Corey; R L Ashley
Journal:  Infect Dis Obstet Gynecol       Date:  1996
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.